AEON Biopharma (AEON) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CytoMed Therapeutics (GDTC) has outperformed AEON Biopharma (AEON) over the past year, losing 59.8% versus a loss of 85.2%. AEON Biopharma is the larger company by market cap ($10.3 million vs $9.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | GDTC |
|---|---|---|
| Share price | $0.123 | $0.755 |
| Market cap | $10.35M | $9.01M |
| 1-day change | -7.59% | -2.33% |
| YTD return | -88.82% | -43.45% |
| 1-year return | -85.18% | -59.84% |
| EPS (TTM) | $-3.89 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $252.26K |
| Revenue growth (YoY) | — | +395.88% |
| Net income (latest FY) | $-39.22M | $-3.10M |
| Net margin | — | -1227.07% |
| 52-week high | $1.45 | $2.12 |
| 52-week low | $0.106 | $0.68 |
| Distance from 52-week high | -91.52% | -64.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1379.67% | +450.99% |
| Average volume | 7.44M | 15.69K |
| Shares outstanding | 84.12M | 11.93M |
| Employees | 8 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GDTC has outperformed AEON by 25.3 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
AEON vs GDTC FAQ
Which is bigger, AEON Biopharma or CytoMed Therapeutics?
AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $9.01M for CytoMed Therapeutics (GDTC).
Which stock has performed better over the past year, AEON or GDTC?
GDTC returned -59.84% over the past 12 months, compared with -85.18% for AEON (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.